PANews reported on February 21 that Kolten, a member of Aave Labs, stated that there has been recent confusion regarding the transition timeline from Aave V3 toPANews reported on February 21 that Kolten, a member of Aave Labs, stated that there has been recent confusion regarding the transition timeline from Aave V3 to

Aave clarifies the transition schedule between V3 and V4: V3 will continue to operate normally in the short term.

2026/02/21 21:48
1 min read

PANews reported on February 21 that Kolten, a member of Aave Labs, stated that there has been recent confusion regarding the transition timeline from Aave V3 to Aave V4. He emphasized that Aave V3 will not be shut down in the foreseeable future and will continue to operate normally even after the launch of Aave V4. There is currently no hard and fast timeline for "replacing V3 with V4 as soon as possible." Kolten stated that V4, based on years of protocol iteration since V1 and extensive business communication experience with institutions and developers, will adopt a slow and cautious launch path on the mainnet, involving "deposit caps and gradual opening of assets and use cases." Kolten also revealed that the team is developing a solution for migrating from V3 to V4 without liquidating positions, but this may not be available on the first day of the V4 mainnet launch.

Market Opportunity
AaveToken Logo
AaveToken Price(AAVE)
$123
$123$123
+1.05%
USD
AaveToken (AAVE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.